BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Biotechnology and Pharmaceutical ChannelMedical Device and Diagnostics ChannelClinical Research Channel
Nektar Therapeutics (NQ: NKTR)
12.26 USD  +1.21 (+10.95%)
Official Closing Price  /  Updated: 8:10 PM EDT, Apr 22, 2014  /  Add to My Watchlist      
(NKTR) Community Analysis from
Bulls REASONS TO BUY
Bears REASONS TO SELL
April 22, 2014
Well it was just one of those days. Zero for three so I closed shop and went out to enjoy the day. I followed the plan and was stopped out on all three trades. Losses were cut...(read more)
(Benzinga, 11/5/10)
Hapoalim Securities raised its price target on Nektar Therapeutics (NASDAQ: NKTR) to $19 from $16. It is reiterating its Buy rating on shares. In a note to clients, Hapoalim writes, "After the impressive Phase II ovarian and breast...(read more)
(Benzinga, 11/2/10)
Below are the top drug delivery stocks on the NYSE and the NASDAQ in terms of cash. Hospira Inc (NYSE: HSP) had $1.15 billion in total cash for the latest quarter. HSP's total debt stood at $2.24 billion in the same period. Elan...(read more)
Nektar Therapeutics (NKTR) Company Overview

There is no analysis for NKTR yet. But you can go to Wikinvest to help create one!


Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here